Tarlatamab for small cell lung cancer brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have small cell lung cancer that has spread to other parts of your body (metastatic SCLC).
- You have at least one untreated brain tumor that is at least 5mm wide and is not causing symptoms.
- You have had chemotherapy with a platinum drug before, with or without immunotherapy.
- You are 18 or older and able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This study collects blood samples from people with small cell lung cancer or neuroendocrine tumors who are being treated with tarlatamab. The goal is to learn more about how the drug works in the body.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.